HemoSense Signs Agreement for INRatio Distribution in Canada

  
    
  
  
    
      HemoSense, Inc. (AMEX:HEM) today announced that it has signed an 
      agreement with ManthaMed, a Canadian provider of health screening, 
      monitoring and diagnostic testing technologies, to market and distribute 
      HemoSense’s portable INRatio® 
      PT/INR monitoring system for patient self-testing and healthcare 
      professionals in Canada. The agreement with ManthaMed represents the 
      Company’s 16th international distribution 
      agreement and expands HemoSense’s 
      international distribution reach to 23 countries.
    
    
      “We believe that entry into the Canadian 
      market represents a significant growth opportunity with an estimated 
      600,000 patients on warfarin therapy,” said 
      Timothy Still, executive VP and chief commercial officer of HemoSense. “ManthaMed’s 
      experience in point-of-care diagnostics and patient monitoring make 
      INRatio a natural addition to their product line.”
    
    
      Peter Mantha, president of ManthaMed added, “As 
      a distributor devoted to improving patient access to reliable and 
      accurate medical technologies, we are delighted to introduce the INRatio 
      system to the Canadian market. We trust that many professionals in 
      physicians’ offices and anticoagulation 
      patients who self-test at home will find INRatio a convenient and 
      appealing alternative to traditional laboratory testing methods.”
    
    
      About HemoSense
    
    
      HemoSense is a point-of-care diagnostic healthcare company that 
      develops, manufactures and markets easy-to-use, handheld blood 
      coagulation systems for monitoring patients taking warfarin. The 
      HemoSense INRatio(R) system, used by healthcare professionals and 
      patients themselves, consists of a small monitor and disposable test 
      strips. It provides accurate and convenient measurement of blood 
      clotting time, or PT/INR values. Routine measurements of PT/INR are 
      necessary for the safe and effective management of the patient’s 
      warfarin dosing. INRatio is sold in the United States and 
      internationally. For more information, visit www.hemosense.com.
    
    
      About ManthaMed
    
    
      ManthaMed is a privately-owned Canadian company with offices in 
      Mississauga, Ontario. ManthaMed distributes diagnostic and monitoring 
      solutions throughout Canada providing state-of-the-art technology and 
      point-of-care management tools designed to evaluate the risk factors of 
      cardiovascular and respiratory disease. These monitoring solutions are 
      provided to patients and healthcare professionals. ManthaMed’s 
      current products include: clinical blood pressure monitors, lipid and 
      glucose management systems, ultrasound dopplers and spirometers. For 
      more information, visit www.manthamed.com.
    
    
      This press release contains forward-looking statements within the 
      meaning of the U.S. Private Securities Litigation Reform Act of 1995. 
      Statements in this press release regarding the Company’s 
      business that are not historical facts may be "forward-looking 
      statements" that involve risks and uncertainties. Specifically, 
      statements regarding the Company’s ability to 
      grow significantly as a result of entry into the Canadian market are 
      forward-looking statements within the meaning of the Safe Harbor. 
      Forward-looking statements are based on management’s 
      current, preliminary, expectations and are subject to risks and 
      uncertainties which may cause the actual results to differ materially 
      from the statements contained herein. Further information on the Company’s 
      business and risk factors are detailed in its filings with the 
      Securities and Exchange Commission, including its Form 10-Q filed on 
      February 13, 2007. Undue reliance should not be placed on these 
      forward-looking statements, which speak only as of the date they are 
      made. The Company undertakes no obligation to update publicly any 
      forward-looking statements to reflect new information, events or 
      circumstances after the date they were made, or to reflect the 
      occurrence of unanticipated events.
    
    
      HemoSense® and INRatio® 
      are registered trademarks of HemoSense, Inc.